PARP makers search for a way to break through

PARP makers search for a way to break through

Source: 
Biopharma Dive
snippet: 

Third quarter results from AstraZeneca, Clovis Oncology and Tesaro suggest that while PARP inhibitors are making some strides on the market, the drug class has yet to become the commercial success Wall Street thought it would be not too long ago.